EC: Scrutiny Leads to Decline in ‘Problematic’ Patent Deals
The number of patent settlements between brand- and generic-drug makers considered by the European Commission (EC) to be “potentially problematic” has fallen since the commission increased its scrutiny of the deals, a new report says.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.